J84.83
Surfactant mutations of the lung
Clinical Classification Guidelines
Medical Intelligence & Overview
Surfactant mutations of the lung refer to genetic changes affecting the production or function of pulmonary surfactant, a substance vital for normal lung function. These mutations can lead to difficulties in breathing and are often associated with various lung conditions, especially in newborns and young children. Recognizing the role of surfactant and its mutations helps in understanding certain respiratory disorders that can impact quality of life and require medical attention.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting genes involved in surfactant production, such as SFTPB, SFTPC, or ABCA3 Inheritance patterns, often autosomal recessive, leading to familial cases Potential environmental factors that may influence surfactant function in susceptible individuals
Key Symptoms: Rapid or labored breathing, especially in infants and young children Cyanosis, which is a bluish tint to the skin due to low oxygen levels Persistent respiratory distress or fatigue during breathing Recurrent respiratory infections If left untreated, symptoms may progress to respiratory failure
Diagnostic & Treatment
Diagnosis Path: Diagnosis of surfactant mutations involves a combination of approaches, including: - Detailed medical and family history to identify inherited patterns - Chest X-rays or CT scans revealing characteristic lung changes - Genetic testing to identify mutations in surfactant-related genes - Analysis of lung tissue samples, if necessary, to observe surfactant deficiency or abnormalities - Monitoring of oxygen levels and lung function tests to assess breathing capacity
Treatment Protocols: Currently, treatment primarily focuses on managing symptoms and supporting lung function: - Oxygen therapy to improve oxygen levels - Mechanical ventilation in severe cases to assist breathing - Administration of medications such as corticosteroids or surfactant replacement therapy in specific situations - Supportive care including nutritional support and prevention of infections - Ongoing monitoring to assess lung growth and function Research into targeted genetic therapies is ongoing, with the hope of developing more precise treatments in the future.
Clinical Advice & FAQs
Billing Guidance
Is J84.83 a billable ICD-10 code?
Yes, J84.83 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report J84.83?
Clinical documentation must specify the nature of Surfactant mutations of the lung and any associated comorbidities for accurate reporting.
Cite this Clinical Reference